Cargando…

Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients

BACKGROUND: The objective of this study was to investigate cellular bioenergetics in primary skin fibroblasts derived from patients with amyotrophic lateral sclerosis (ALS) and to determine if they can be used as classifiers for patient stratification. METHODS: We assembled a collection of unprecede...

Descripción completa

Detalles Bibliográficos
Autores principales: Konrad, Csaba, Kawamata, Hibiki, Bredvik, Kirsten G., Arreguin, Andrea J., Cajamarca, Steven A., Hupf, Jonathan C., Ravits, John M., Miller, Timothy M., Maragakis, Nicholas J., Hales, Chadwick M., Glass, Jonathan D., Gross, Steven, Mitsumoto, Hiroshi, Manfredi, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655870/
https://www.ncbi.nlm.nih.gov/pubmed/29065921
http://dx.doi.org/10.1186/s13024-017-0217-5
_version_ 1783273619768475648
author Konrad, Csaba
Kawamata, Hibiki
Bredvik, Kirsten G.
Arreguin, Andrea J.
Cajamarca, Steven A.
Hupf, Jonathan C.
Ravits, John M.
Miller, Timothy M.
Maragakis, Nicholas J.
Hales, Chadwick M.
Glass, Jonathan D.
Gross, Steven
Mitsumoto, Hiroshi
Manfredi, Giovanni
author_facet Konrad, Csaba
Kawamata, Hibiki
Bredvik, Kirsten G.
Arreguin, Andrea J.
Cajamarca, Steven A.
Hupf, Jonathan C.
Ravits, John M.
Miller, Timothy M.
Maragakis, Nicholas J.
Hales, Chadwick M.
Glass, Jonathan D.
Gross, Steven
Mitsumoto, Hiroshi
Manfredi, Giovanni
author_sort Konrad, Csaba
collection PubMed
description BACKGROUND: The objective of this study was to investigate cellular bioenergetics in primary skin fibroblasts derived from patients with amyotrophic lateral sclerosis (ALS) and to determine if they can be used as classifiers for patient stratification. METHODS: We assembled a collection of unprecedented size of fibroblasts from patients with sporadic ALS (sALS, n = 171), primary lateral sclerosis (PLS, n = 34), ALS/PLS with C9orf72 mutations (n = 13), and healthy controls (n = 91). In search for novel ALS classifiers, we performed extensive studies of fibroblast bioenergetics, including mitochondrial membrane potential, respiration, glycolysis, and ATP content. Next, we developed a machine learning approach to determine whether fibroblast bioenergetic features could be used to stratify patients. RESULTS: Compared to controls, sALS and PLS fibroblasts had higher average mitochondrial membrane potential, respiration, and glycolysis, suggesting that they were in a hypermetabolic state. Only membrane potential was elevated in C9Orf72 lines. ATP steady state levels did not correlate with respiration and glycolysis in sALS and PLS lines. Based on bioenergetic profiles, a support vector machine (SVM) was trained to classify sALS and PLS with 99% specificity and 70% sensitivity. CONCLUSIONS: sALS, PLS, and C9Orf72 fibroblasts share hypermetabolic features, while presenting differences of bioenergetics. The absence of correlation between energy metabolism activation and ATP levels in sALS and PLS fibroblasts suggests that in these cells hypermetabolism is a mechanism to adapt to energy dissipation. Results from SVM support the use of metabolic characteristics of ALS fibroblasts and multivariate analysis to develop classifiers for patient stratification. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13024-017-0217-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5655870
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56558702017-10-31 Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients Konrad, Csaba Kawamata, Hibiki Bredvik, Kirsten G. Arreguin, Andrea J. Cajamarca, Steven A. Hupf, Jonathan C. Ravits, John M. Miller, Timothy M. Maragakis, Nicholas J. Hales, Chadwick M. Glass, Jonathan D. Gross, Steven Mitsumoto, Hiroshi Manfredi, Giovanni Mol Neurodegener Research Article BACKGROUND: The objective of this study was to investigate cellular bioenergetics in primary skin fibroblasts derived from patients with amyotrophic lateral sclerosis (ALS) and to determine if they can be used as classifiers for patient stratification. METHODS: We assembled a collection of unprecedented size of fibroblasts from patients with sporadic ALS (sALS, n = 171), primary lateral sclerosis (PLS, n = 34), ALS/PLS with C9orf72 mutations (n = 13), and healthy controls (n = 91). In search for novel ALS classifiers, we performed extensive studies of fibroblast bioenergetics, including mitochondrial membrane potential, respiration, glycolysis, and ATP content. Next, we developed a machine learning approach to determine whether fibroblast bioenergetic features could be used to stratify patients. RESULTS: Compared to controls, sALS and PLS fibroblasts had higher average mitochondrial membrane potential, respiration, and glycolysis, suggesting that they were in a hypermetabolic state. Only membrane potential was elevated in C9Orf72 lines. ATP steady state levels did not correlate with respiration and glycolysis in sALS and PLS lines. Based on bioenergetic profiles, a support vector machine (SVM) was trained to classify sALS and PLS with 99% specificity and 70% sensitivity. CONCLUSIONS: sALS, PLS, and C9Orf72 fibroblasts share hypermetabolic features, while presenting differences of bioenergetics. The absence of correlation between energy metabolism activation and ATP levels in sALS and PLS fibroblasts suggests that in these cells hypermetabolism is a mechanism to adapt to energy dissipation. Results from SVM support the use of metabolic characteristics of ALS fibroblasts and multivariate analysis to develop classifiers for patient stratification. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13024-017-0217-5) contains supplementary material, which is available to authorized users. BioMed Central 2017-10-24 /pmc/articles/PMC5655870/ /pubmed/29065921 http://dx.doi.org/10.1186/s13024-017-0217-5 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Konrad, Csaba
Kawamata, Hibiki
Bredvik, Kirsten G.
Arreguin, Andrea J.
Cajamarca, Steven A.
Hupf, Jonathan C.
Ravits, John M.
Miller, Timothy M.
Maragakis, Nicholas J.
Hales, Chadwick M.
Glass, Jonathan D.
Gross, Steven
Mitsumoto, Hiroshi
Manfredi, Giovanni
Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients
title Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients
title_full Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients
title_fullStr Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients
title_full_unstemmed Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients
title_short Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients
title_sort fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655870/
https://www.ncbi.nlm.nih.gov/pubmed/29065921
http://dx.doi.org/10.1186/s13024-017-0217-5
work_keys_str_mv AT konradcsaba fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients
AT kawamatahibiki fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients
AT bredvikkirsteng fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients
AT arreguinandreaj fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients
AT cajamarcastevena fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients
AT hupfjonathanc fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients
AT ravitsjohnm fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients
AT millertimothym fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients
AT maragakisnicholasj fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients
AT haleschadwickm fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients
AT glassjonathand fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients
AT grosssteven fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients
AT mitsumotohiroshi fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients
AT manfredigiovanni fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients